What Is MOTS-c? Research Evidence & Profile

What Is MOTS-c?

MOTS-c is a mitochondrial-derived peptide identified by the MOTS-c designation. This page identifies the material as Mitochondrial-Derived Peptide MOTS-c, with amino acid count 16; synonyms MOTS-c. The MOTS-c identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

8ClinicalTrials.gov query records

258PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for MOTS-c is organized around mitochondrial-derived peptide research, cellular energy-pathway studies, peptide characterization, and analytical peptide workflows. For MOTS-c, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT06133946Cohort Of DEafness-gene Screening	Not stated	Active Not Recruiting	Hearing Loss	2023-11-18
NCT07678073Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation	NA	Recruiting	Kidney Disease, End-Stage, Kidney Transplant, Kidney, Kidney Disease, Renal Transplant	2026-07-08
NCT07505745MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity	Phase 2	Recruiting	Prediabetes, Insulin Resistance, Overweight/Obesity	2026-04-01
NCT06500975Long Term Outcomes After Vestibular Implantation	NA	Recruiting	Bilateral Vestibular Hypofunction, Bilateral Vestibular Deficiency, Bilateral Vestibulopathy, Gentamicin Ototoxicity, Aminoglycoside Toxicity, Vestibular Diseases, Sensation Disorders, Labyrinth Diseases, Other Disorders of Vestibular Function	2026-03-09
NCT07438002Analysis of Effects of High-intensity Physical Exercise in Subjects With Dialyzed Chronic Kidney Disease and in Conservative Treatment	NA	Recruiting	Chronic Kidney Disease	2026-02-27
NCT03878706The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination	Not stated	Recruiting	Diabetes Mellitus, Type 2	2026-03-13

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

Frontiers in endocrinology · 2023

PMID 36761202

Selected PubMed record

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.

Cell metabolism · 2015 Mar 3

PMID 25738459

Selected PubMed record

Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024 Nov

PMID 39321430

Selected PubMed record

MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism.

Free radical biology & medicine · 2025 Dec 16

PMID 41043625

Selected PubMed record

MOTS-c attenuates airway barrier dysfunction in allergic asthma by inhibiting epithelial apoptosis via Nrf2 pathway.

International immunopharmacology · 2025 Aug 28

PMID 40472776

Selected PubMed record

Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.

Frontiers in physiology · 2025

PMID 40661667

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Mitochondrial-Derived Peptide MOTS-c
Available Specifications: 10mg, 15mg, 20mg, 40mg
Pack Format: 10 Vials
CAS Number: 1627580-64-6
Molecular Formula: C101H152N28O22S2
Molecular Weight: 2174.55 g/mol
Amino Acid Count: 16
Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
Synonyms: MOTS-c
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 146675088 · Product form must still be matched to the catalogue and batch record.

Research Tools for MOTS-c

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

MOTS-c Research Summary

Identity

Mitochondrial-Derived Peptide MOTS-c; specifications: 10mg, 15mg, 20mg, 40mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

8 registry records and 258 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

MOTS-c is represented here by the catalogue identity Mitochondrial-Derived Peptide MOTS-c. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg, 15mg, 20mg, 40mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for MOTS-c is organized around mitochondrial-derived peptide research, cellular energy-pathway studies, peptide characterization, and analytical peptide workflows. For MOTS-c, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 8 ClinicalTrials.gov records and 258 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

MOTS-c FAQ

What is MOTS-c?

What research records are indexed for MOTS-c?

The synchronized query returned 8 ClinicalTrials.gov records and 258 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is MOTS-c FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.